Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin

Απλή σελίδα τεκμηρίου
dc.contributor.authorNaka, K. K.en
dc.contributor.authorPapathanassiou, K.en
dc.contributor.authorBechlioulis, A.en
dc.contributor.authorPappas, K.en
dc.contributor.authorKazakos, N.en
dc.contributor.authorKanioglou, C.en
dc.contributor.authorPapafaklis, M. I.en
dc.contributor.authorKostoula, A.en
dc.contributor.authorVezyraki, P.en
dc.contributor.authorMakriyiannis, D.en
dc.contributor.authorTsatsoulis, A.en
dc.contributor.authorMichalis, L. K.en
dc.date.accessioned2015-11-24T18:53:05Z
dc.date.available2015-11-24T18:53:05Z
dc.identifier.issn1752-8984-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18493
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAnalysis of Varianceen
dc.subjectBiological Markers/blooden
dc.subjectBlood Glucose/drug effects/metabolismen
dc.subjectChi-Square Distributionen
dc.subjectDiabetes Mellitus, Type 2/blood/*drug therapy/physiopathologyen
dc.subjectDrug Therapy, Combinationen
dc.subjectEndothelium, Vascular/*drug effects/physiopathologyen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHemoglobin A, Glycosylated/metabolismen
dc.subjectHumansen
dc.subjectHypoglycemic Agents/*therapeutic useen
dc.subjectInsulin/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectThiazolidinediones/*therapeutic useen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.subjectVasodilation/*drug effectsen
dc.titleRosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulinen
heal.abstractAn increased incidence of myocardial infarction with rosiglitazone in patients with type 2 diabetes mellitus (T2DM) has been reported. This study aimed to assess the effect of rosiglitazone on endothelial function, assessed by flow-mediated dilation (FMD), in 34 patients with advanced T2DM treated with insulin without known cardiovascular disease. Patients were randomised into two groups: no additional treatment was given in 17 patients, while 17 patients were given rosiglitazone for 6 months. Addition of rosiglitazone significantly reduced glycosylated haemoglobin (HbA(1c)) (p < 0.0005) and fasting glucose (p < 0.05) and improved FMD (p < 0.005). No significant changes were observed in the insulin-only group. The single independent predictor of FMD improvement was rosiglitazone treatment (p = 0.048). These results show that, in patients with advanced T2DM treated with insulin, addition of rosiglitazone may have a beneficial effect on endothelial function. Further research is needed to investigate why this beneficial effect does not translate into improved cardiovascular prognosis in these patients.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1177/1479164111408628-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21576196-
heal.identifier.secondaryhttp://dvr.sagepub.com/content/8/3/195.full.pdf-
heal.journalNameDiab Vasc Dis Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ